Agenus Inc.
Anti-TIGIT antibodies and methods of use thereof
Last updated:
Abstract:
The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Status:
Grant
Type:
Utility
Filling date:
1 May 2018
Issue date:
1 Jun 2021